secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001725160-23-000131
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis announces azenosertib monotherapy RP2D with 36.8% ORR in ovarian/USC
-----------------------------------------------------------------------------

- RP2D set at 400 mg QD on 5:2 schedule; steady-state exposure more than doubled vs continuous dosing.
- Confirmed ORR 36.8% (7/19) in ovarian/USC with intermittent dosing vs 19.2% (5/26) continuous.
- No discontinuations due to TRAEs in intermittent cohorts; improved tolerability over continuous dosing.
- Three Phase 2 monotherapy trials enrolling: Cyclin E1+ ovarian, USC, PARPi-resistant ovarian cancer.
- Company plans H2 2023 update on Phase 1 dose optimization data and Phase 2 program timelines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000131/0001725160-23-000131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000131/zntl-20230606.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer